Hologic [HOLX] vs ResMed [RMD] Detailed Stock Comparison

Hologic

NASDAQ
Loading...

ResMed

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Hologic wins in 6 metrics, ResMed wins in 13 metrics, with 0 ties. ResMed appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricHologicResMedBetter
P/E Ratio (TTM)27.8628.41Hologic
Price-to-Book Ratio3.086.65Hologic
Debt-to-Equity Ratio52.0914.27ResMed
PEG Ratio5.780.94ResMed
EV/EBITDA12.4721.14Hologic
Profit Margin (TTM)13.79%27.22%ResMed
Operating Margin (TTM)25.48%33.87%ResMed
EBITDA Margin (TTM)25.48%33.87%ResMed
Return on Equity11.38%25.86%ResMed
Return on Assets (TTM)6.69%14.02%ResMed
Free Cash Flow (TTM)$1.15B$1.65BResMed
Dividend YieldN/A0.63%N/A
1-Year Return-15.37%18.23%ResMed
Price-to-Sales Ratio (TTM)3.707.71Hologic
Enterprise Value$15.57B$39.33BResMed
EV/Revenue Ratio3.867.64Hologic
Gross Profit Margin (TTM)56.32%60.84%ResMed
Revenue per Share (TTM)$18$35ResMed
Earnings per Share (Diluted)$2.41$9.54ResMed
Beta (Stock Volatility)0.570.85Hologic
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Hologic vs ResMed Stock Performance Analysis

Loading Price Chart...

Hologic
ResMed
Hologic Stock Overview | ResMed Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Hologic1.30%3.22%1.95%4.00%12.14%-5.34%
ResMed2.14%3.49%2.08%8.11%24.05%21.08%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Hologic-15.37%6.51%-2.13%82.16%322.59%379.59%
ResMed18.23%24.38%57.07%409.47%747.03%1,327.45%

News Based Sentiment: Hologic vs ResMed

Hologic

News based Sentiment: NEUTRAL

The month's news for Hologic paints a picture of stability rather than dramatic growth. While the stock outperformed the S&P 500 slightly and analyst estimates are trending upward, the overall sentiment is neutral due to the 'Hold' rating and modest gains. The valuation metrics suggest potential value, but don't indicate a strong buy signal.

View Hologic News Sentiment Analysis

ResMed

News based Sentiment: POSITIVE

ResMed experienced a strong September, marked by positive Q4 earnings, increased dividend payouts, and multiple analyst upgrades, including a 'strong-buy' rating from UBS and a 'Buy' rating with a $330 target from Citigroup. While insider selling occurred, the overall narrative is positive, supported by robust financial performance and strategic initiatives.

View ResMed News Sentiment Analysis

Performance & Financial Health Analysis: Hologic vs ResMed

MetricHOLXRMD
Market Information
Market Cap i$14.94B$40.08B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i3,267,260840,530
90 Day Avg. Volume i2,018,787936,663
Last Close$67.91$276.64
52 Week Range$51.90 - $84.39$199.92 - $293.81
% from 52W High-19.53%-5.84%
All-Time High$87.88 (May 01, 2023)$301.34 (Sep 06, 2021)
% from All-Time High-22.72%-8.20%
Growth Metrics
Quarterly Revenue Growth0.01%0.10%
Quarterly Earnings Growth0.00%0.30%
Financial Health
Profit Margin (TTM) i0.14%0.27%
Operating Margin (TTM) i0.25%0.34%
Return on Equity (TTM) i0.11%0.26%
Debt to Equity (MRQ) i52.0914.27
Cash & Liquidity
Book Value per Share (MRQ)$21.79$40.77
Cash per Share (MRQ)$8.47$8.26
Operating Cash Flow (TTM) i$1.07B$1.75B
Levered Free Cash Flow (TTM) i$760.11M$1.21B
Dividends
Last 12-Month Dividend Yield iN/A0.63%
Last 12-Month Dividend iN/A$1.59

Valuation & Enterprise Metrics Analysis: Hologic vs ResMed

MetricHOLXRMD
Price Ratios
P/E Ratio (TTM) i27.8628.41
Forward P/E i14.2326.34
PEG Ratio i5.780.94
Price to Sales (TTM) i3.707.71
Price to Book (MRQ) i3.086.65
Market Capitalization
Market Capitalization i$14.94B$40.08B
Enterprise Value i$15.57B$39.33B
Enterprise Value Metrics
Enterprise to Revenue i3.867.64
Enterprise to EBITDA i12.4721.14
Risk & Other Metrics
Beta i0.570.85
Book Value per Share (MRQ) i$21.79$40.77

Financial Statements Comparison: Hologic vs ResMed

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)HOLXRMD
Revenue/Sales i$1.01B$1.35B
Cost of Goods Sold i$628.00M$527.93M
Gross Profit i$377.30M$820.07M
Research & Development i$61.50M$86.44M
Operating Income (EBIT) i$37.90M$456.57M
EBITDA i$121.70M$532.89M
Pre-Tax Income i$-28.50M$458.05M
Income Tax i$-11.10M$78.35M
Net Income (Profit) i$-17.40M$379.71M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)HOLXRMD
Cash & Equivalents i$1.43B$1.21B
Total Current Assets i$3.21B$3.51B
Total Current Liabilities i$989.70M$1.02B
Long-Term Debt i$2.47B$811.41M
Total Shareholders Equity i$4.62B$5.97B
Retained Earnings i$3.03B$6.08B
Property, Plant & Equipment i$939.80M$288.62M

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)HOLXRMD
Operating Cash Flow i$28.40M$441.40M
Capital Expenditures i$-24.70M$-30.59M
Free Cash Flow i$129.20M$504.99M
Debt Repayment i$-10.20M$-5.00M
Common Stock Repurchase i$-200.00M$-100.01M

Short Interest & Institutional Ownership Analysis

MetricHOLXRMD
Shares Short i3.11M8.65M
Short Ratio i2.038.77
Short % of Float i0.02%0.07%
Average Daily Volume (10 Day) i3,267,260840,530
Average Daily Volume (90 Day) i2,018,787936,663
Shares Outstanding i231.73M146.39M
Float Shares i220.32M145.48M
% Held by Insiders i0.01%0.01%
% Held by Institutions i1.01%0.65%

Dividend Analysis & Yield Comparison: Hologic vs ResMed

MetricHOLXRMD
Last 12-Month Dividend iN/A$1.59
Last 12-Month Dividend Yield iN/A0.63%
3-Year Avg Annual Dividend iN/A$1.60
3-Year Avg Dividend Yield iN/A0.23%
3-Year Total Dividends iN/A$4.79
Ex-Dividend DateN/AFeb 13, 2025